Business
TherapeuticsMD Announces First Quarter 2025 Financial Results
BOCA RATON, Fla., May 13, 2025--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2025.
About this update from Therapeuticsmd, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/b4c3758e77b312c9b2992d6c812427be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rvmbT3jK7HoB7v_kIjp0Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b4c3758e77b312c9b2992d6c812427be","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/HymsmBBjstYC96ibZn6HfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/b4c3758e77b312c9b2992d6c812427be","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BOCA RATON, Fla., May 13, 2025--(BUSINESS WIRE)--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2025.","length":273,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Financial Results","length":36,"tagName":"p"},{"type":"text","content":"Net Loss from Continuing Operations","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net loss from continuing operations was $(636) thousand, or $(0.06) per basic and diluted common share, a decrease of $99 thousand, compared to net loss from continuing operations of $(809) thousand, or $(0.07) per basic and diluted common share, for the first quarter of 2024.","length":277,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":277,"olType":false},{"type":"text","content":"License Revenues from Continuing Operations","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"License revenue, primarily from the Mayne License Agreement, totaled $393 thousand for the first quarter ended March 31, 2025, an increase of $80 thousand, or 25.8%, compared to $313 thousand in license revenue for the three months ended March 31, 2024. The increase is primarily attributable to changes in sales of licensed products.","length":334,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":334,"olType":false},{"type":"text","content":"Total Operating Expenses from Continuing Operations","length":51,"tagNa...